# First siRNA Therapy Approved for Myasthenia Gravis

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/neurology/generalneurology/123972) · 2026-11-19 · Medicine
Page: https://themorning.science/story/first-sirna-therapy-approved-for-myasthenia-gravis-228c8aefa19d9e6a
Kind: launch · Impact: medium

## In brief

- The FDA approved subcutaneous cemdisiran, branded Livsayis, for generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody-positive.
- Cemdisiran is a small interfering RNA (siRNA) therapy, the first siRNA treatment approved for myasthenia gravis according to the headline.
- The approval was announced by Regeneron.

## Why it matters

It establishes siRNA, a gene-silencing approach, as a clinically approved option for an autoimmune neuromuscular disease, which may matter for other antibody-mediated conditions being studied with similar therapies.

## Coverage

- [First siRNA Therapy Approved for Myasthenia Gravis](https://www.medpagetoday.com/neurology/generalneurology/123972) — MedPageToday.com - medical news for physicians, 2026-11-19

Tags: myasthenia gravis, sirna, neurology, fda approval, regeneron, autoimmune disease

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
